当前位置: X-MOL 学术BMJ › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Future of screening for prostate cancer
The BMJ ( IF 93.6 ) Pub Date : 2017-09-19 , DOI: 10.1136/bmj.j4200
Philipp Dahm 1
Affiliation  

Multiparametric magnetic resonance imaging is likely to be part of it Few topics in medicine stir up as much controversy as prostate cancer screening. Prostate cancer is a highly prevalent, potentially lethal disease, making the enthusiasm of the public and health professionals for screening and treatment understandable.1 However, many screen detected cancers have a protracted and indolent natural course with no adverse effects for decades, and patients are at greater risk from the ensuing cascade of diagnostic imaging and unnecessary treatments than from the disease itself. Current best evidence suggests that prostate specific antigen (PSA) testing provides only a small reduction in prostate cancer mortality and no reduction in all cause mortality, while at the same time exposing healthy individuals to the risk of overdiagnosis and overtreatment.2 Recent draft recommendations by the United States Preventive Services Task Force against population based screening (grade C), emphasise the importance of shared decision making between men and their healthcare providers but fall short of providing other actionable guidance.3 Although the results of the CAP …

中文翻译:

前列腺癌筛查的未来

多参数磁共振成像可能是其中的一部分,很少有医学话题能像前列腺癌筛查一样引起如此多的争议。前列腺癌是一种高度流行、可能致命的疾病,这使得公众和卫生专业人员对筛查和治疗的热情是可以理解的。1 然而,许多筛查检测到的癌症具有长期和惰性的自然病程,几十年来没有任何副作用,患者与疾病本身相比,随之而来的一系列诊断成像和不必要的治疗带来的风险更大。目前最好的证据表明,前列腺特异性抗原 (PSA) 检测仅能小幅降低前列腺癌死亡率,而不会降低全因死亡率,
更新日期:2017-09-19
down
wechat
bug